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decreased oxygen consumption, thrombocytopenia, and
leukopenia.3,4 However, protamine is still used routinely
to reverse heparin anticoagulation. It is commonly
believed that too much protamine is deleterious, but the
mechanism is not fully understood. 
In this study, we focus on platelet function to evaluate
the effect of low-dose protamine relative to the heparin
dose after cardiopulmonary bypass (CPB). 
Material and methods
Heparin used in this study was from gut mucosa (Novo
Nordisk A/S, Bagsvaerd, Denmark), and we considered that 1
unit of heparin was equivalent to 10 m g of protamine (Novo
Nordisk). 
Phase I (ex vivo, patient analysis). From August 1997 to
August 1998, platelet function during CPB was evaluated in
42 patients who were selected randomly at the University of
Tsukuba Hospital. Informed consent was obtained from all
patients enrolled in this protocol. They did not receive any
antiplatelet drugs within 7 days before the operation and
P rotamine, a mixture of simple proteins (molecularweight, 4,000-10,000) is isolated from fish sperm,
which contains a high percentage (>70%) of arginine.1
Highly acidic heparin combines stoichiometrically with
the base protamine, resulting in a neutral inactive salt.2
Protamine sulfate has numerous and infrequently fatal
side effects such as systemic arterial hypotension,
peripheral vasodilation, bradycardia, decreased cardiac
output, pulmonary artery hypotension or hypertension,
Objective: The heparin-protamine titration method that uses the Hepcon
hemostasis management system (Medtronic HemoTec Inc, Englewood,
Colo) reduced blood loss in cardiac surgery in previous reports, but the
mechanism is not fully understood. This study tests the hypothesis that
reduced protamine administration preserves platelet function in human
cardiac surgery. Methods: Platelet count, a -granule secretion, and aggre-
gation to thrombin before and after cardiopulmonary bypass in human
beings were evaluated. In the control group (n = 14), a fixed dose of prot-
amine (3 mg/kg) was administered. In the titration group (n = 20), prota-
mine doses were based on the heparin concentration measured by the
Hepcon system. Results: Heparin concentrations before protamine admin-
istration were higher in the titration group (P = .0012), but protamine
doses of patients in the titration group were markedly lower than those of
the control group (P < .0001). During protamine infusion at a rate of 0.3
mg · kg–1 · min–1, the percentage of granule membrane protein-140–posi-
tive platelets significantly increased in the control group compared with
the titration group (18.8% ± 8.6% vs 13.0% ± 5.3%, P = .0188). After pro-
tamine administration, aggregation of washed platelets to thrombin
recovered almost to the preoperative level in the titration group; however,
it remained lower in the control group (20% ± 20% vs 55% ± 18%, P =
.0009). Conclusion: Low-dose administration of protamine, based on a
heparin-protamine titration method, restores not only the blood coagula-
tion but also the platelet responses to thrombin and attenuates platelet a -
granule secretion during heparin neutralization. Overdose of protamine
activates platelets and may predispose patients to excessive bleeding after
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underwent CPB without aprotinin. All patients were anes-
thetized with an opioid-based technique (fentanyl citrate).
Extracorporeal circulation was accomplished with a roller
pump and a membrane oxygenator (HPO-25RHF, Mera,
Japan). Systemic hypothermia was maintained at 30°C to
32°C during aortic crossclamping. The CPB circuit was rou-
tinely primed with 1.5 L of Veen-D solution (glucose-acetate
Ringer’s solution), sodium bicarbonate (NaHCO3) 33 mEq/L,
mannitol 27 mg/L, and heparin 3.3 units/mL. 
Among 42 patients, 8 patients (6 patients in the control
group and 2 patients in the titration group) were excluded
because of blood transfusion including platelets before the
last samples were obtained. For patients in the control group
(n = 14), the anticoagulation and reversal protocol consisted
of an initial fixed heparin dose of 300 U/kg, 5000 units of
heparin added to the priming fluid of the CPB circuit, and
additional heparin administered when the celite activated
clotting time (ACT) was less than 480 seconds. The prota-
mine dose for the control group was fixed at 3 mg/kg and
administered at a rate of 0.3 mg · kg–1 · min–1. For the titra-
tion group (n = 20), we administered the same dose of initial
and priming heparin that we used in the control group
because the heparin dose-response test by the Hepcon hemo-
stasis management system (Medtronic HemoTec Inc,
Englewood, Colo) sometimes underestimates the initial
heparin doses. Additional heparin was administered when the
heparin concentration measured by the Hepcon system was
less than 2.7 units/mL or the celite ACT was less than 480
seconds. The neutralizing dose of protamine was based on the
whole blood heparin concentration measurement using the
Hepcon system, which performs heparin-protamine titration
automatically within 5 minutes in the operating room. On the
basis of the heparin concentration of the sample after discon-
tinuation of CPB, 1.0 mg of protamine per 100 units of resid-
ual heparin for total volume was administered at the same rate
as in the control group. All patients underwent the operation
uneventfully.
Sample preparation. Five milliliters of blood was collect-
ed from patients at 4 separate points: before the operation,
after discontinuation of CPB but before protamine adminis-
tration, at the end of protamine administration, and 15 min-
utes after protamine administration. All specimens from each
patient were stored at room temperature until the last speci-
men was obtained, and then they were analyzed together. So
that the platelet function test could be completed within 4 to
5 hours after the first specimen was collected, specimens in
subsequent postoperative intervals (2–6 hours postoperative-
ly) were not obtained. The blood was transferred into a
syringe containing 0.75 mL of acid-citrate-dextrose (ACD)
solution (citric acid, 6.8 mmol/L; trisodium citrate, 11.2
mmol/L; glucose, 24 mmol/L) and mixed gently. All the spec-
imens were centrifuged at 180g for 10 minutes just after the
final sample was obtained. A 200 m L solution of platelet-rich
plasma (PRP) was fixed with 200 m L of 2% paraformalde-
hyde (E. Merck, Darmstadt, Germany) for flow cytometric
analysis. The rest of the PRP was washed for platelet aggre-
gation study.
Washed platelets. PIPES buffer (piperazine-N-N´-bis[2-
ethanesulfonic acid]) was prepared to wash the platelets or
dilute the antibodies (PIPES buffer, 5 mmol/L [Dojindo,
Tokyo, Japan]; NaCl, 145 mmol/L; KCl, 4 mmol/L; Na2HPO4,
0.5 mmol/L; MgCl2, 1 mmol/L; glucose, 5.5 nmol/L; bovine
albumin, 3.5 mg/mL; pH 7.4). The PRP was mixed with an
equal volume of washing buffer (1:8 = ACD solution/PIPES
buffer) and then centrifuged at 400g for 15 minutes at room
temperature. The platelet pellet was resuspended gently in
PIPES buffer at a concentration of 2.0 · 108/mL for the assay
of thrombin-induced platelet aggregation. 
Phase II (in vitro, volunteer analysis). For in vitro stud-
ies, 10 mL of venous blood from healthy volunteers, who had
no medication for at least 10 days before donation, was col-
lected into plastic tubes containing 1.5 mL ACD buffer. The
blood was centrifuged at 180g for 10 minutes at room tem-
perature and PRP was collected. The PRP was washed 2
times in the same way as in the in vivo study. 
Detection of platelet surface cluster of differentiation
(CD62) by flow cytometric analysis. Platelet surface antigen
was stained by the phycoerythrin-labeled monoclonal anti-
body and analyzed by flow cytometry (FACSort; Becton
Dickinson, Mountain View, Calif). The monoclonal antibody
used in this study was CD62-PE (Becton Dickinson), a mon-
oclonal antibody that recognizes a -granule membrane pro-
tein (GMP-140) expressed on the platelet surface after
platelet secretion. A 20-m L aliquot of each fixed platelet sam-
ple was incubated with 5 m L of 1:5 diluted monoclonal anti-
body (saturating concentration of the antibody) in the dark
for 30 minutes at room temperature to allow antibody bind-
ing, and then 400 m L of ISOTON II solution (Coulter, Inc,
Tokyo, Japan) was added to dilute the samples. 
The samples were first analyzed by forward scatter (>350)
and side scatter (>450). A gate was set so as to include the
majority of the platelets and exclude larger particles, which
may be platelet aggregates or other contaminating blood
cells. A fluorescence histogram was obtained for 10,000
Table I. Demographic and operative data
Control Titration 
(n = 14) (n = 20) P value
Age (y) 51.7 ± 22.6 55.2 ± 20.5 NS
Male sex (n) 10 14
Weight (kg) 46.6 ± 18.6 56.6 ± 13.3 NS
CPB time (h) 2.4 ± 0.6 2.7 ± 0.7 NS
Heparin dose: final 458 ± 100 537 ± 973 .0132
(U/kg)
Heparin concentration* 1.39 ± 0.32 2.13 ± 0.63 .0012
(U/mL)
Protamine dose (mg/kg) 3.00 1.77 ± 0.56 <.0001
Protamine/heparin ratio 0.67 ± 0.15 0.33 ± 0.09 <.0001
Postoperative bleeding† 12.3 ± 8.6 8.7 ± 6.5 NS
(mL/kg)
Values are mean ± SD. CPB, Cardiopulmonary bypass; NS, not significant.
*Heparin concentration evaluated by Hepcon system before protamine admin-
istration.
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cells. Platelet a -granule secretion was monitored by detect-
ing GMP-140 (CD62) expression on platelet surface. The
threshold level for GMP-140–negative cells was set so as to
include 99% of nonstained platelets. 
Because of sedimentary formation, the washed platelets
that were incubated with protamine (in vitro study) were
stained directly without fixation by paraformaldehyde.
Platelet aggregation. Platelet aggregation was studied
with a Hema Tracer device (SSR Engineering Co Ltd, Tokyo,
Japan). The threshold concentration of thrombin (ie, the low-
est concentration of the agonist capable of producing irre-
versible aggregation of at least 60% to 70% light transmis-
sion of buffer in 5 minutes) was determined with the sample
obtained before the operation. The same concentration of
thrombin was used to determine the percent aggregation of
washed platelets in all subsequent samples.
b -Thromboglobulin concentration. In the in vitro study,
400 m L of washed platelets (1.0 · 109/mL) was incubated
with protamine (up to 100 m g/mL) for 5 minutes at room tem-
perature. After being mixed with 100 m L of ACD solution, the
sample was centrifuged at 400g for 15 minutes and the super-
natant was stored at –20°C. The concentration of b -throm-
boglobulin in the supernatant was measured with the enzyme-
linked immunosorbent assay kits (Diagnostica, Stago,
France). 
Statistical analysis. The results in Table I were expressed
as the mean ± standard deviation. The effects of protamine on
GMP-140 expression and platelet aggregation at various
times during the operation were expressed as the mean ±
standard error and compared by the Student unpaired t test
and analysis of variance with Bonferroni correction.
Results
Phase I (ex vivo, patient analysis). No differences
between the groups were identified with regard to demo-
Fig 1. Time course of hematologic values (mean ± SE). CPB, Cardiopulmonary bypass; P, protamine infusion at
a rate of 0.3 mg · kg–1 · min–1. The duration of protamine infusion was 10 minutes in control group and about 5
minutes in titration group. s-s, Control group (n = 14); d-d, titration group (n = 20). *P < .05 between con-
trol and titration groups by the Student unpaired t test at given times. A, Whole blood activated clotting time; B,
platelet count; C, CD62-FITC (monoclonal antibodies to GMP-140) positive platelets (percent); and D, washed
platelet aggregation to thrombin. The concentrations of thrombin were 0.12 ± 0.06 unit/mL in the control group
and 0.10 ± 0.03 unit/mL in the titration group.
A B
C D
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graphic data and duration of CPB (Table I). Titration
group patients received greater doses of heparin than
control group patients and had significantly higher con-
centrations of heparin after CPB. By contrast, mean pro-
tamine dose administered in the titration group was sig-
nificantly lower than that in the control group. 
Additional heparin was administered when ACTs
were less than 480 seconds and, as a result, each ACT
during CPB was kept at more than 400 seconds in both
groups (Fig 1, A). Although the protamine doses
administered in titration group patients were about half
the doses of the control group, the ACTs in the titration
group returned to 108% of the baseline values at the
end of protamine infusion. In addition, the ACTs in the
titration group (115 ± 11 seconds) were less than those
in the control group (121 ± 20 seconds) 15 minutes
after protamine administration. No heparin rebound
was observed, and additional protamine doses were not
required in either group. 
Compared with samples obtained before protamine
administration, whole blood platelet counts in the titra-
tion group showed only an 8% decrease at the end of
protamine administration, whereas platelet counts in
the control group decreased 13% temporarily (Fig 1,
B). The percentages of GMP-140–positive platelets
significantly increased in control group patients but
remained lower in titration group patients at the end of
protamine administration (Fig 1, C). 
The threshold concentrations of thrombin that caused
60% to 70% aggregation in the samples obtained
before the operation were 0.12 ± 0.06 unit/mL in con-
trol group patients and 0.10 ± 0.03 unit/mL in titration
group patients. The aggregation of washed platelets to
thrombin was suppressed during CPB in both groups;
however, 80% recovery of aggregation compared with
baseline values was observed after protamine infusion
in the titration group (Fig 1, D). In contrast, the per-
centage remained lower (<26%) after protamine
administration in control group patients.
Fig 2. Effect of protamine on platelet a -granule secretion (A) and b -thromboglobulin (B). Washed platelets were
incubated with protamine for 5 minutes at room temperature and fixed with 1% paraformaldehyde followed by
flow cytometric or enzyme-linked immunosorbent assay analysis.
A B
Fig 3. Washed platelets were incubated with buffer (s-s), 1
unit/mL (s -s ) or 3 units/mL (¤ -¤ ) of heparin for 5 minutes
followed by incubation with protamine (up to 60 m g/mL) for
5 minutes at room temperature. Then, platelet aggregation
induced by thrombin (0.1 unit/mL) was measured by a Hema
Tracer device. 
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Phase II (in vitro, volunteer analysis). Protamine,
incubated with washed platelets for 5 minutes at room
temperature, increased the percentage of GMP-140-
positive platelets (Fig 2, A) and b -thromboglobulin
release (Fig 2, B) in a concentration-related manner.
These results indicate that a protamine threshold
between 1 and 10 m g/mL caused the a -granule secre-
tion of washed platelets. 
To evaluate the influence of heparin and protamine
on platelet aggregation, we incubated washed platelets
with buffer or heparin (1-3 units/mL) for 5 minutes at
room temperature followed by incubation with prota-
mine (up to 60 m g/mL) for 5 minutes at 37°C. Then
platelet aggregation stimulated by 0.1 unit/mL of
thrombin was measured (Fig 3). In the sample without
heparin, low-dose protamine (>5 m g/mL) reduced the
aggregation of washed platelets stimulated by throm-
bin. Heparin itself slightly attenuated the platelet
aggregation to thrombin, which suspended in the buffer
without antithrombin III. Lower concentration of prot-
amine relative to heparin concentration restored the
platelet aggregation to thrombin that was impaired by
heparin. However, excess concentration of protamine
compared with heparin lessened the aggregation of
washed platelets to thrombin. Protamine (10 m g/mL)-
related platelet inhibition was overcome by greater
doses (>0.3 unit/mL) of thrombin, but there was a time
lag (about 5 minutes) to the start of aggregation after
thrombin injection. 
Discussion 
Protamine itself, not heparin or the protamine-heparin
complex, is responsible for its multifactorial toxicity.5
Protamine has been found to be toxic to endothelial cells
and cardiac myocytes, and it has been shown to enter the
interstitium of organs such as the heart, directly affecting
cellular function.6 Mechanisms suggested to explain tox-
icity have included direct vasodilation and depression
of cardiac function,7 release of histamine,3 immuno-
logic abnormalities,8 generation of thromboxane,9 inhi-
bition of carboxypeptidase N in the plasma,2 and activa-
tion of complement.10 Total cationic charge appears to
be an important determinant for both anticoagulation
reversal and toxicity of protamine-like peptides.11
The effects of protamine on platelets also have been
well documented. Jaques12 in 1949 reported significant
thrombocytopenia associated with protamine adminis-
tration. Machi, Sigel, and Feinberg13 showed that
platelet aggregation was induced by protamine before
clots formed and that not only shear rate but also
platelet activation might affect the rate and composi-
tion of plasma clots. Wakefield, Whitehouse, and
Stanley14 reported that platelet count decreased by up
to 74% after reversal of heparinization with protamine
in dogs. In this study, platelet counts of control group
patients did not decrease significantly after protamine
administration. The reason may be that the protamine
doses were not based on the total heparin doses but
rather on the initial heparin doses. Lindblad and col-
leagues15 studied the effect of protamine sulfate on
platelet function and found that protamine inhibits
thrombin-induced platelet aggregation. Ammar and
Fisher4 reported that platelet reactivity to thrombin
receptor agonist peptide was markedly inhibited by
protamine. Both heparin and protamine attenuate
platelet aggregation to thrombin, but the mechanisms
are quite different. Our in vitro study showed that pro-
tamine threshold between 1 and 10 m g/mL released a -
granules of washed platelets; in other words, protamine
activated platelets. Although increased thrombin con-
centration (>0.3 unit/mL) may aggregate washed
platelets after incubation with protamine, it is unclear
whether these concentrations are achieved either local-
ly or systemically in vivo.16 In contrast, heparin did not
release a -granules of washed platelets (data not
shown), and the attenuated platelet aggregation to
thrombin was restored by an adequate amount of prot-
amine. These findings indicated that there may be two
separate mechanisms for preservation of platelet func-
tion during CPB: higher heparin concentration and
lower protamine concentration. 
To prevent protamine toxicity, attempts have been
undertaken to produce positively charged designer pep-
tides that would safely reverse standard unfractionated
heparin.11 Other approaches for reversal of heparin
anticoagulation unrelated to protamine exist, such as
platelet factor 4,17,18 heparinase,4 and filter systems,19
but they too have limitations.20 Because protamine sul-
fate is the only current agent approved by the Food and
Drug Administration for intraoperative reversal of
heparin anticoagulation,20 appropriate administration
of protamine after CPB is important to reduce its side
effects. For example, slow protamine administration
decreased the magnitude of the adverse responses,21
and reduced protamine doses were associated with sig-
nificant decreases in blood product use and postopera-
tive bleeding.22,23 Despotis and associates24 indicated
that greater doses of heparin and lower doses of prota-
mine relative to heparin dose, based on the point-of-
care monitoring of heparin concentration by an auto-
mated protamine sulfate titration method, were
associated with reduced blood use. They suggest that
this effect is due partly to better preservation of the
coagulation system, including platelet function. 
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At present, when protamine is used to reverse stan-
dard-unfractionated heparin anticoagulation, two prac-
tical approaches may be used: a fixed dose of prota-
mine (such as 1.2 to 1.5 mg/100 IU of previously
administered heparin) or a technique called protamine
titration, in which the amount of protamine adminis-
tered is directly matched to the amount of heparin cir-
culating at the time of reversal.20 Advantages of the
second approach with protamine titration include a
lessening of the amount of protamine with a potential
decrease in toxicity, and disadvantages include the
potential for bleeding from heparin rebound and the
subsequent need to administer more protamine.20 In
this study, protamine doses in the titration group were
less than half the doses in the control group and one
third of the values that were based on whole heparin
doses. Nevertheless, the ACTs in titration group
patients returned to almost normal range, and no signs
of heparin rebound were observed. The data on heparin
concentration by the Hepcon system showed that
heparin concentration decreased during CPB, even
though ACTs were kept higher than 400 seconds. The
reason is that the ACTs are prolonged not only by
heparin but also by hemodilution or hypothermia. As a
result, protamine doses based on the initial heparin
doses exceed the residual heparin doses in control
group patients. GMP-140–positive platelet studies and
platelet aggregation to thrombin in the control group
indicate that excess protamine, compared with heparin
concentration before protamine administration, activat-
ed platelets and attenuated platelet aggregation to
thrombin. In the titration group, lower doses of prota-
mine than the heparin dose restored platelet reactivity
to thrombin that was depressed during CPB. These data
imply that appropriate protamine administration for
reversal of heparin anticoagulation preserves platelet
function and may reduce blood product use.
Conclusions
Administration of the minimum required dose of pro-
tamine based on the protamine-heparin titration data
reduces platelet activation and preserves platelet
responses to thrombin after CPB. Protamine might be
used more safely and effectively by the automated
heparin-protamine titration method. 
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